Evidence map›Paper›PMID 30583691›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2018

Lymph Node Ratio: Is It an Independent Prognostic Factor for Stage III Cutaneous Melanoma?

Abolfazl Salari, Fatemeh Nili, Amir Mohsen Jalaeefar, Mohammad Shirkhoda

Abstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Abolfazl SalariCancer Research Center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Email: mshirkhoda@sina.tums.ac.ir
Fatemeh Nili
Amir Mohsen Jalaeefar
Mohammad Shirkhoda

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Lymph node ratio (LNR) is defined as the ratio of the number of metastatic lymph nodes to the dissected lymph nodes. LNR is a prognostic factor for many tumor types. The present study aimed to evaluate the prognostic value of LNR in melanoma. Methods: This retrospective cohort study was conducted on 123 patients with stage III cutaneous melanoma. Multivariate Cox proportional hazards model was used to evaluate the correlations between LNR and other clinicopathological factors associated with survival. The patients were divided into four groups in terms of the LNR, including groups A (LNR≤0.18), B (0.18<LNR≤0.37), C (0.37<LNR≤0.625), and D (LNR>0.625). Results: Initially, LNR was evaluated as a continuous quantity associated with survival. In the univariate analysis, a significant correlation was observed between LNR, overall survival (OS), and disease free survival (DFS). Meanwhile, the only association observed in the multivariate analysis was between LNR and OS. Increased LNR from group A to group D reduced OS from 46 (±44.09) to 22.5 (±16.33) months (P=0.022). According to the multivariate analysis, prognostic factors in OS were tumor thickness, American joint committee of cancer (AJCC) N stage, interferon administration, and undergoing chemotherapy. Conclusion: According to the results, LNR could be used as an independent prognostic factor for estimating the survival of patients with stage III cutaneous melanoma also designing an effective adjuvant treatment protocol for these patients.

Indexed as

Cutaneous Malignant MelanomaDisease-Free SurvivalFemaleHumansLymphatic MetastasisLymph Node ExcisionLymph NodesMaleMelanomaMiddle AgedMultivariate AnalysisNeoplasm StagingPrognosisProportional Hazards ModelsRetrospective StudiesSkin NeoplasmsCutaneous melanomalymph node dissectionlymph node ratio

Identifiers

PMID30583691
PMCPMC6428529

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.